Exeliom Biosciences Announces Series A Extension and Final Closing with Total of €24 Million
Funding to advance clinical development of its lead candidate in immuno-oncology and infectious diseases
05-Jul-2023 -
Exeliom Biosciences (formerly Nextbiotix), a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies, announced the completion of its €24 million ($26 million) Series A with a last extension of €8 ...
cancer
immunotherapies
infectious diseases
+1